TABLE 1.
Characteristics of 361 solid organ transplant recipients treated with bebtelovimab or sotrovimab for mild‐to‐moderate coronavirus disease 2019 (COVID‐19)
| Bebtelovimab (N = 92) | Sotrovimab (N = 269) | Total (N = 361) | |
|---|---|---|---|
| Age, mean (SD), years | 59.7 (14.0) | 56.9 (14.8) | 57.7 (14.6) |
| Female sex | 37 (40.2) | 102 (37.9) | 139 (38.5) |
| Race (N = 360) | |||
| ‐ American Indian or Alaska Native | 0 (0) | 3 (1.1) | 3 (0.8) |
| ‐ Asian | 3 (3.3) | 10 (3.7) | 13 (3.6) |
| ‐ Black or African American | 4 (4.3) | 26 (9.7) | 30 (8.3) |
| ‐ Native Hawaiian or Other Pacific Islander | 0 (0) | 4 (1.5) | 4 (1.1) |
| ‐ White | 85 (92.4) | 222 (82.8) | 307 (85.3) |
| ‐ Other | 0 (0) | 3 (1.1) | 3 (0.8) |
| Hispanic or Latino ethnicity (N = 357) | 5 (5.4) | 25 (9.4) | 30 (8.4) |
| Transplant Type | |||
| ‐ Heart | 23 (25.0) | 39 (14.5) | 62 (17.2) |
| ‐ Kidney | 34 (37.0) | 119 (44.2) | 153 (42.4) |
| ‐ Liver | 22 (23.9) | 57 (21.2) | 79 (21.9) |
| ‐ Lung | 4 (4.3) | 17 (6.3) | 21 (5.8) |
| ‐ Pancreas | 0 (0) | 2 (0.7) | 2 (0.6) |
| ‐ Multiorgan a | 9 (9.8) | 35 (13.0) | 44 (12.2) |
| Subsequent transplant | 8 (8.7) | 36 (13.4) | 44 (12.2) |
| Time from transplant, median (IQR), years | 5.6 (2.0, 10.8) | 4.0 (1.6, 9.4) | 4.4 (1.7, 9.8) |
| Body mass index, median (IQR), kg/m2 | 28.3 (25.8, 32.1) | 27.9 (24.0, 32.0) | 28.0 (24.1, 32.0) |
| Diabetes mellitus | 36 (39.1) | 105 (39.0) | 141 (39.1) |
| Chronic pulmonary disease | 12 (13.0) | 29 (10.8) | 41 (11.4) |
| MASS, median (IQR) | 9.0 (6.0, 10) | 8.0 (6.0, 10) | 8.0 (6.0, 10) |
| Charlson comorbidity index, median (IQR) | 4.0 (2.0, 5.0) | 4.0 (2.0, 5.0) | 4.0 (2.0, 5.0) |
| Vaccination status | |||
| ‐ Booster vaccine dose | 42 (45.7) | 11 (4.1) | 53 (14.7) |
| ‐ Fully vaccinated, unboosted | 26 (28.3) | 167 (62.1) | 193 (53.5) |
| ‐ Partially vaccinated | 11 (12.0) | 56 (20.8) | 67 (18.6) |
| ‐ Unvaccinated | 13 (14.1) | 35 (13.0) | 48 (13.3) |
| Vaccine manufacturer (N = 313) | |||
| ‐ Johnson & Johnson | 3 (3.8) | 12 (5.1) | 15 (4.8) |
| ‐ Moderna | 34 (43.0) | 93 (39.7) | 127 (40.6) |
| ‐ Pfizer‐BioNTech | 42 (53.2) | 129 (55.1) | 171 (54.6) |
| Time from last vaccine dose to diagnosis, median (IQR), days | 104.0 (68.0, 220.5) | 140 (98.2, 158.0) | 137.0 (89.0, 162.0) |
| Time from diagnosis to monoclonal antibody infusion, median (IQR), days | 1.0 (1.0, 2.0) | 2.0 (1.0, 3.0) | 2.0 (1.0, 3.0) |
Data are N (%)unless otherwise specified.
Abbreviations: IQR, interquartile range; MASS, monoclonal antibody screening score; SD, standard deviation.
a
Multiorgan transplants include kidney‐pancreas (17), heart‐kidney (12), liver‐kidney (11), heart‐liver (2), and heart‐lung (2).